ALK and adenocarcinoma: In the prostate, this conversion has been observed in up to 25% of adenocarcinomas that develop resistance to anti-androgen therapies [143,148], and in the lung has been observed in 3–14% of adenocarcinomas that develop resistance to targeted EGFR inhibitors [141,149,150], as well as to inhibitors of ALK, ROS1, and RET kinases and immunotherapy [144].